{"id":5875,"date":"2016-11-28T09:51:48","date_gmt":"2016-11-28T14:51:48","guid":{"rendered":"https:\/\/fomatmedical.com\/?p=5875"},"modified":"2026-04-27T15:19:14","modified_gmt":"2026-04-27T22:19:14","slug":"skin-cancer-prevention","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/skin-cancer-prevention\/","title":{"rendered":"Nueva inmunoterapia t\u00f3pica eficaz contra el c\u00e1ncer de piel en fase inicial"},"content":{"rendered":"
\n
\n

Skin Cancer Prevention: 5 Alarming Facts About a Breakthrough Topical Immunotherapy<\/strong><\/h2>\n<\/div>\n<\/div>\n
\n
\n

Skin cancer prevention has taken a significant step forward with new research from Washington University School of Medicine in St. Louis and Harvard Medical School. A combination of two topical drugs has been shown to trigger a powerful immune response against precancerous skin lesions \u2014 reducing them by nearly 88 percent on the face compared to just 26 percent with standard treatment.<\/p>\n<\/div>\n<\/div>\n

\n
\n

The study, published in The Journal of Clinical Investigation, involved patients with actinic keratosis, a common precancerous condition that can develop into squamous cell carcinoma if left untreated. The findings represent one of the most promising advances in skin cancer prevention research in recent years.<\/p>\n<\/div>\n<\/div>\n

\n
\n

What Is Actinic Keratosis and Why Does It Matter for Skin Cancer Prevention?<\/strong><\/h2>\n<\/div>\n<\/div>\n
\n
\n

Actinic keratosis refers to rough, scaly patches on sun damaged skin that appear most commonly on the face, scalp, and arms. While these lesions are not yet full skin cancers, they have the potential to progress into squamous cell carcinoma \u2014 making their treatment a critical component of any skin cancer prevention strategy.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Current standard treatment uses a chemotherapy cream called 5-fluorouracil applied over two to four weeks. While effective in some patients, its results are inconsistent and the treatment period is long. The new investigational therapy addresses both of those limitations.<\/p>\n<\/div>\n<\/div>\n

\n
\n

5 Alarming Facts About This Skin Cancer Prevention Breakthrough<\/strong><\/h2>\n<\/div>\n<\/div>\n
\n
\n

Fact 1: The New Therapy Reduced Precancerous Lesions by Up to 88 Percent<\/strong><\/h3>\n<\/div>\n<\/div>\n
\n
\n

The most striking finding in this skin cancer prevention study is the magnitude of lesion reduction achieved by the investigational therapy. On the face, the combination treatment reduced precancerous lesions by nearly 88 percent compared to just 26 percent with the standard chemotherapy cream.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Results were similarly dramatic across other body sites. On the scalp, the reduction was 76 percent versus 6 percent for the control group. On the right arm, the investigational therapy produced a 69 percent reduction compared to 10 percent for the control. On the left arm, the reduction was 79 percent versus 16 percent. These numbers represent a substantial improvement in skin cancer prevention outcomes across all sites examined.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Fact 2: The Treatment Works in Just 4 Days Instead of 4 Weeks<\/strong><\/h3>\n<\/div>\n<\/div>\n
\n
\n

Standard 5-fluorouracil treatment for precancerous lesions requires application over two to four weeks. The new skin cancer prevention therapy achieves superior results in just four days of twice daily application \u2014 a dramatic reduction in treatment burden for patients.<\/p>\n<\/div>\n<\/div>\n

\n
\n

This compressed treatment window is possible because the combination therapy works differently than conventional chemotherapy alone. Rather than relying solely on a chemical attack on precancerous cells, it activates the immune system to do much of the work.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Fact 3: The Therapy Activates the Immune System’s T Cells to Attack Abnormal Cells<\/strong><\/h3>\n<\/div>\n<\/div>\n
\n
\n

The investigational therapy combines 5-fluorouracil with calcipotriol, a synthetic form of vitamin D that is already FDA approved for psoriasis treatment. Calcipotriol causes the skin to produce a protein called TSLP, which activates T cells \u2014 the immune system’s front line defenders against abnormal and cancerous cells.<\/p>\n<\/div>\n<\/div>\n

\n
\n

When the 5-fluorouracil destroys precancerous cells, those cells release proteins called antigens. The immune system, already primed by calcipotriol, then mounts an aggressive attack on those antigens and any remaining abnormal cells. This immune activation approach is central to the skin cancer prevention mechanism of the new therapy.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Fact 4: The Immune Response May Provide Lasting Protection<\/strong><\/h3>\n<\/div>\n<\/div>\n
\n
\n

One of the most exciting implications of this skin cancer prevention research is the possibility that the activated T cells could retain memory of the precancerous antigens they encountered during treatment. If confirmed, this immunological memory could provide ongoing protection against future development of both precancerous and cancerous skin lesions.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Study co-author Dr. Lynn A. Cornelius of Washington University’s Division of Dermatology noted that the research team is now planning to recontact study participants to determine whether the two treatment groups show differences in long term rates of precancerous and cancerous skin lesions \u2014 a follow up that could confirm the lasting skin cancer prevention benefits of the immune based approach.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Fact 5: The Study Involved 132 Patients in a Randomized Controlled Trial<\/strong><\/h3>\n<\/div>\n<\/div>\n
\n
\n

This skin cancer prevention study was not a small preliminary experiment. It involved 132 patients with actinic keratosis treated at Washington University School of Medicine. Sixty five patients were randomly assigned to receive the investigational combination of 5-fluorouracil and calcipotriol, while 67 patients served as the control group receiving the standard 5-fluorouracil plus petroleum jelly.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Patients began the trial with similar numbers of precancerous lesions across all body sites examined, with an average of approximately 15 lesions on the face, 22 on the scalp, 14 on the right arm, and 12 on the left arm. The statistically significant reductions observed in the investigational group across all sites provide strong evidence for this therapy as a meaningful skin cancer prevention advance.<\/p>\n<\/div>\n<\/div>\n

\n
\n

What This Means for Skin Cancer Prevention Going Forward<\/strong><\/h2>\n<\/div>\n<\/div>\n
\n
\n

This research establishes a new direction in the treatment of precancerous skin lesions \u2014 one that harnesses the immune system rather than relying solely on cytotoxic chemotherapy. The combination of greater efficacy, shorter treatment duration, and the possibility of lasting immune protection makes this approach particularly promising for patients at high risk of skin cancer.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Additional clinical trials will be needed to confirm long term skin cancer prevention outcomes and to evaluate the therapy across broader patient populations. For more information on active dermatology and oncology studies, visit ClinicalTrials.gov<\/a> and the Skin Cancer Foundation<\/a>.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Participate in Clinical Research With FOMAT Medical<\/strong><\/h2>\n<\/div>\n<\/div>\n
\n
\n

At FOMAT Medical, we support Phase I through Phase IV clinical studies across multiple therapeutic areas throughout the United States, including oncology and dermatology research. Advances in skin cancer prevention depend on the clinical trial participation of patients willing to contribute to the science that protects future generations.<\/p>\n<\/div>\n<\/div>\n

\n
\n

If you or someone you know may be interested in joining an active clinical study, explore our currently available trials.<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Skin Cancer Prevention: 5 Alarming Facts About a Breakthrough Topical Immunotherapy Skin cancer prevention has taken a significant step forward with new research from Washington University School of Medicine in St. Louis and Harvard Medical School. A combination of two topical…<\/p>","protected":false},"author":3,"featured_media":93175,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[968],"tags":[975,1129,1130,1131],"class_list":["post-5875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-cancer","tag-immunotherapy","tag-melanoma","tag-skin-cancer"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/5875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=5875"}],"version-history":[{"count":0,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/5875\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/93175"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=5875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=5875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=5875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}